Product Description
ImmunoVec's ARPA-H-funded project will apply the company's platform to develop a novel polymeric nanoparticle capable of engineering natural killer (NK) cells in vivo with a CD19-targeted chimeric antigen receptor (CAR) construct. This approach aims to deplete B cells that cause autoimmune disease (autoreactive cells), and offers significant advantages over traditional ex vivo CAR therapies. (Sourced from: https://immunovec.com/news/arpa-h-award)
Mechanisms of Action: CAR-T, CD19
Novel Mechanism: No
Modality: In Vivo CAR-T
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Immunovec
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Autoimmune Disease Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|